Literature DB >> 9286739

Progestogen intolerance and compliance with hormone replacement therapy in menopausal women.

N Panay1, J Studd.   

Abstract

It is vital that we maximize compliance if patients are to receive the full benefits from hormone replacement therapy (HRT). One of the main factors for reduced compliance is that of progestogen intolerance. Progestogens have a variety of effects apart from the one for which their use was intended, that of secretory transformation of the endometrium. Endometrial effects vary between individuals and between different progestogens, leading to bleeding problems. Symptoms of fluid retention are produced by the sodium-retaining effect on the renin-aldosterone system. The nor-testosterone-derived progestogens can have adverse effects on skin, lipids, vasculature and insulin resistance. Negative mood effects are produced by most progestogens due to the effect on neurotransmitters via central nervous system progesterone receptors. Manipulation of the dosage and duration of progestogen, continuous administration of a low dose of progestogen and a reduction in the number of progestogenic episodes can be used to improve compliance. The progestogen and progesterone releasing coils and vaginal progesterone gel minimize systemic side effects and bleeding. Adverse effects can also be avoided by making use of the progesterone receptor-specific progestogens such as the pregnanes (e.g. cyproterone), nor-pregnanes (e.g. nomegestrol) and progesterone itself. Hysterectomy remains an option for the severely progestogen-intolerant woman. In the future, progestogen intolerance may not be an issue if selective oestrogen receptor modulators provide a complete alternative to HRT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286739     DOI: 10.1093/humupd/3.2.159

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  11 in total

Review 1.  Transdermal estradiol for postpartum depression: a promising treatment option.

Authors:  Eydie L Moses-Kolko; Sarah L Berga; Brinda Kalro; Dorothy K Y Sit; Katherine L Wisner
Journal:  Clin Obstet Gynecol       Date:  2009-09       Impact factor: 2.190

2.  Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995.

Authors:  M T Connelly; M Richardson; R Platt
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

Review 3.  Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  M P Curran; A J Wagstaff
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Headache and hormone replacement therapy in the postmenopausal woman.

Authors:  E Anne MacGregor
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

5.  Lowered Plasma Steady-State Levels of Progesterone Combined With Declining Progesterone Levels During the Luteal Phase Predict Peri-Menstrual Syndrome and Its Major Subdomains.

Authors:  Chutima Roomruangwong; André F Carvalho; Frank Comhaire; Michael Maes
Journal:  Front Psychol       Date:  2019-10-30

6.  Real world data on symptomology and diagnostic approaches of 27,840 women living with endometriosis.

Authors:  Kerstin Becker; Klaas Heinemann; Bruno Imthurn; Lena Marions; Sabine Moehner; Christoph Gerlinger; Marco Serrani; Thomas Faustmann
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

Review 7.  Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review.

Authors:  Sebastián Carranza-Lira
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

Review 8.  Acute and Preventive Management of Migraine during Menstruation and Menopause.

Authors:  Raffaele Ornello; Eleonora De Matteis; Chiara Di Felice; Valeria Caponnetto; Francesca Pistoia; Simona Sacco
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

Review 9.  Abnormal bleeding during menopause hormone therapy: insights for clinical management.

Authors:  Sebastião Freitas de Medeiros; Márcia Marly Winck Yamamoto; Jacklyne Silva Barbosa
Journal:  Clin Med Insights Womens Health       Date:  2013-01-23

10.  The effect of low-dose combined hormone therapy (oestradiol and norethindrone acetate) on serum C-reactive protein levels and life quality in natural menopause women.

Authors:  Servin Gocer; Suleyman Guven; Hidayet Sal; Emine Seda Guvendag Guven
Journal:  Prz Menopauzalny       Date:  2021-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.